Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10
- PMID: 16618775
- DOI: 10.1158/0008-5472.CAN-05-3825
Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10
Abstract
The development of effective immunotherapeutic strategies for central nervous system (CNS) tumors requires a firm understanding of factors regulating the trafficking of tumor antigen-specific CTLs into CNS tumor lesions. Using C57BL/6 mice bearing intracranial (i.c.) ovalbumin-transfected melanoma (M05), we evaluated the efficacy and tumor homing of i.v. transferred type 1 or 2 CTLs (Tc1 or Tc2, respectively) prepared from ovalbumin-specific T-cell receptor-transgenic OT-1 mice. We also tested our hypothesis that intratumoral (i.t.) delivery of dendritic cells that had been transduced with IFN-alpha cDNA (DC-IFN-alpha) would enhance the tumor-homing and antitumor effectiveness of adoptively transferred Tc1 via induction of an IFN-gamma-inducible protein 10 (IP-10). In vitro, DC-IFN-alpha induced IP-10 production by M05 and enhanced the cytolytic activity of Tc1. In vivo, i.v. transferred Tc1 trafficked efficiently into i.c. M05 and mediated antitumor responses more effectively than Tc2, and their effect was IP-10 dependent. I.t. injections of DC-IFN-alpha remarkably enhanced the tumor homing, therapeutic efficacy, and in situ IFN-gamma production of i.v. delivered Tc1, resulting in the long-term survival and persistence of systemic ovalbumin-specific immunity. These data suggest that Tc1-based adoptive transfer therapy may represent an effective modality for CNS tumors, particularly when combined with strategies that promote a type 1 polarized tumor microenvironment.
Similar articles
-
Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.Cancer Res. 2004 Aug 15;64(16):5830-8. doi: 10.1158/0008-5472.CAN-04-0130. Cancer Res. 2004. PMID: 15313927
-
Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.Gene Ther. 2004 Nov;11(21):1551-8. doi: 10.1038/sj.gt.3302300. Gene Ther. 2004. PMID: 15343358
-
Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.J Immunol. 1999 Jun 1;162(11):6671-80. J Immunol. 1999. PMID: 10352285
-
Brain tumor immunotherapy with type-1 polarizing strategies.Ann N Y Acad Sci. 2009 Sep;1174:18-23. doi: 10.1111/j.1749-6632.2009.04932.x. Ann N Y Acad Sci. 2009. PMID: 19769732 Review.
-
Adoptive immunotherapy of CNS malignancies.Cancer Chemother Biol Response Modif. 2001;19:327-38. Cancer Chemother Biol Response Modif. 2001. PMID: 11686021 Review.
Cited by
-
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.J Transl Med. 2010 Feb 18;8:17. doi: 10.1186/1479-5876-8-17. J Transl Med. 2010. PMID: 20167088 Free PMC article.
-
Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.Clin Cancer Res. 2009 Nov 1;15(21):6551-9. doi: 10.1158/1078-0432.CCR-09-1067. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861464 Free PMC article.
-
Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours.PLoS One. 2013 May 23;8(5):e63933. doi: 10.1371/journal.pone.0063933. Print 2013. PLoS One. 2013. PMID: 23717511 Free PMC article.
-
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.Cancer Immunol Immunother. 2008 Jan;57(1):73-84. doi: 10.1007/s00262-007-0351-y. Epub 2007 Jun 30. Cancer Immunol Immunother. 2008. PMID: 17602226 Free PMC article.
-
CCR7 regulates B16 murine melanoma cell tumorigenesis in skin.J Leukoc Biol. 2008 Oct;84(4):965-72. doi: 10.1189/jlb.1107776. J Leukoc Biol. 2008. PMID: 18519742 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical